Reference materials for ctDNA-based measurable residual disease (MRD) assay development and validation
Monitoring measurable residual disease (MRD) via liquid biopsy is a highly desirable method for catching early stage cancer and disease relapse long before traditional diagnostics, which generally require significant disease progression for detection. Regardless, detection of variant allele frequencies at extremely low levels, well below the limit of detection of typical circulating tumor DNA (ctDNA) assays, presents a challenge. We developed the Seraseq® ctDNA MRD Panel kit composed of 4 tumor fractions at decreasing levels to meet validation needs of both patient specific and fixed panel targeted cfDNA NGS MRD assays. Download this poster presented at AACR 2022 to learn more.